GuidelineEuropean journal of nuclear medicine and molecular imaging2025
Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).
Guideline in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
- Exploration of Chemokine Receptor 4 Targeted [Molecular imaging and biology · 2026Article
- Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review.Cancers · 2026Review
- Nomogram to predict the early postoperative hypoparathyroidism after total thyroidectomy in the thyroid cancer patients of eastern China.Gland surgery · 2026Article
- A cognitive divide in active surveillance acceptance persists between surgeons and endocrinologists managing low-risk thyroid cancer.Scientific reports · 2026Article
- Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects.The oncologist · 2026Review
- Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features.Frontiers in oncology · 2026Article
- Thirty years of NCI thyroid cancer research investment (1996-2025): a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution.Frontiers in oncology · 2026Article
- Systematic adolescent-centered supportive care program is associated with improved psychological status, treatment adherence, and social adaptation in adolescents with thyroid cancer undergoing radioiodine-131 therapy: a retrospective before-after cohort study with historical controls.Frontiers in endocrinology · 2026Article
- Predicting unfavorable response to initial radioactive iodine therapy in differentiated thyroid cancer: an explainable machine learning and survival analysis approach.Frontiers in endocrinology · 2026Article
- Development and validation of a nomogram to predict failure of initial radioactive iodine therapy in differentiated thyroid cancer: a retrospective cohort study.Scientific reports · 2025Article
- High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.Frontiers in oncology · 2025Review
- Efficacy and safety of anlotinib combined withFrontiers in endocrinology · 2025Observational
- Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
purposeRadioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) has become a challenge in clinical practice, particularly in China with a high incidence and undesirable survival outcome. Since the publication of first China consensus on the diagnosis and treatment of RAIR-DTC in 2019, significant and rapid advances have occurred in the field both in China and internationally. This guideline aims to inform Chinese clinicians, researchers, patients, and health policy makers on the latest evidence and recommendations, to further standardize the clinical diagnosis and treatment of RAIR-DTC.
methodsThe structured clinical questions addressed in this guideline were derived from clinical diagnostic and treatment processes, with references to study, prior guidelines, expert consensus, and systematic reviews, etc. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used for quantitative and qualitative evaluation of the evidence. The editorial process was completely independent of the guideline development group.
resultsThe guideline addressed 26 clinical questions and formed 35 recommendations. In this guideline, the definition criteria for RAIR-DTC was optimized, prediction and identification was based on evidence including molecular testing, dynamic biochemical changes, and multimodal imaging. Comprehensive pre-treatment clinical evaluation was emphasized and tailored for individualized decision-making. The combination of systematic therapy and surgery, and the redifferentiation followed by RAI therapy were also reviewed and updated. Molecular imaging plays a unique role in the pre-assessing and therapeutic response evaluation for RAIR-DTC.
conclusionsWe have updated and developed evidence-based recommendations with the aim of providing scientific, rigorous, and comprehensive guidance for the clinical diagnosis and treatment of RAIR-DTC patients in China. We hope to share our guideline with colleagues out of China, with the expectation of further comments and suggestions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.